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ABSTRACT 
AEG-1 KNOCKOUT SENSITIZES HEPATOCELLULAR CARCINOMA (HCC) CELLS 
TO IONIZING RADIATION 
 
A thesis submitted in partial fulfillment of the requirements for the degree of                                               
Master of Science Virginia Commonwealth University, 2019 
 
By MAHEEN H. KHAN, B.S. 
 
ADVISOR: DR. DEVANAND SARKAR, M.B.B.S., Ph.D. 
Professor, Department of Human and Molecular Genetics                                                                
Harrison Foundation Distinguished Professor in Cancer Research                                                                                    
Virginia Commonwealth University 
 
Liver cancer is the fourth leading cause of cancer-associated deaths globally, and among primary 
liver cancers, hepatocellular carcinoma (HCC) encompasses 75-85% of all cases. HCC is a 
highly lethal disease due to limited treatment options – only a small subset of patients qualify for 
surgical resection or transplantation; the remaining patients often display resistance to radiation 
therapy or chemotherapy. Overexpression of the oncogene astrocyte elevated gene-1 (AEG-1) is 
associated with poorer survival and increased tumor recurrence in HCC, and numerous studies 
show its role in initiation of hepatocarcinogenesis. A prior study also demonstrated AEG-1 
expression inhibits senescence by diminishing the ATM/Chk1/Chk2/p53/p21 DNA damage 
response (DDR) pathway. The aim of this study is to understand if AEG-1 expression promotes 
radioresistance in HCC. A CRISPR/Cas9 plasmid system was used to delete AEG-1 in the QGY-
7703, HuH7 and DihXY cell lines, which model HCC. The cell lines were then treated with 
ionizing radiation (IR). We find that knockout of AEG-1 in these cell lines induces sensitivity to 
IR at 2.5 Gy. In response to radiation, AEG-1 wildtype cells more profoundly upregulate ATR, 
Chk1, and Chk2 signaling; and also more rapidly induce γH2AX, ATM, and BRCA1 signaling, 
which sense dsDNA breaks to initiate homologous recombination repair. We conclude that 
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AEG-1 expression protects HCC cells from IR through two mechanisms: 1) rapidly initiating the 
DNA damage response; and 2) increasing replication fork stabilization. These findings indicate 
AEG-1 can be a therapeutic target in combination with radiation treatment to improve outcomes 
for HCC patients who demonstrate radioresistance. 
Keywords: Hepatocellular carcinoma, ionizing radiation, astrocyte elevated gene-1, DNA 
damage response
 
CHAPTER 1 
INTRODUCTION 
Hepatocellular carcinoma 
Liver cancer has the sixth highest incidence of all cancers globally, and is the fourth leading 
cause of cancer-associated deaths. Among males, liver cancer is the second highest cause of 
cancer-related deaths, and has the fifth highest incidence of all cancers. According to the most 
recent global cancer statistics report, approximately 841,000 new cases of liver cancer and 
782,000 liver-cancer-associated deaths are reported world-wide. The incidence of liver cancer is 
increasing in Western nations due to the growing obesity epidemic in these areas – the incidence 
of HCC is strongly associated with diabetes. Among primary liver cancers, hepatocellular 
carcinoma (HCC) encompasses 75-85% of all cases1. 
HCC is often an end-stage liver disease that is secondary to infection by hepatitis B virus (HBV) 
or hepatitis C virus (HCV), both of which lead to chronic inflammation and liver cirrhosis. 50% 
of all HCC cases are attributed to chronic HBV infection. On the other hand, the percentage of 
HCC patients positive for HCV markers varies geographically, with Japan having the highest 
percentage (80-90%). HCC is more prevalent among males partly due to increased incidence of 
viral hepatitis and alcohol-induced cirrhosis; and partly due to hormonal differences, such as 
association between increased testosterone and advanced hepatic cirrhosis, and the protective 
effect of estrogen against HBV infection2. 
Anti-viral treatment reduces recurrence and mortality in patients with HBV-associated HCC, 
while interferon therapy decreases mortality in HCV-associated HCC. Localized HCC can be 
treated with surgical resection, liver transplantation, and radiofrequency ablation. However, these 
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methods are not effective in tumors of advanced symptomatic stages. Systemic treatment of HCC 
is difficult due to its resistance to traditional chemotherapies, including to cisplatin, doxorubicin, 
and 5-fluorouracil. Sorafenib, a multi-kinase inhibitor that targets the serine/threonine kinase 
RAF, is FDA-approved for systemic treatment of patients with advanced HCC; however, a 
clinical trial showed survival was only improved from 7.9 to 10.7 months in sorafenib-treated 
HCC patients. Chemotherapy and radiotherapy are now used as palliative treatment in patients 
with metastatic HCC due to demonstrated resistance to both forms of treatment3,4. The limited 
treatment options make HCC a highly lethal disease. 
HCC initiates from terminally differentiated, rarely-dividing epithelial cells. The most frequent 
genes mutated in HCC are those encoding the proteins p53, c-myc, cyclin D1, BRCA2, APC, 
and PTEN, among others. Activation of the mitogen-activated protein kinase (MAPK) and 
vascular endothelial growth factor (VGEF) pathways are also highly associated with HCC 
tumorigenesis and development. Because HCC tumors show heterogeneity in their activated 
oncogenic signaling pathways and in their mutated genes, it is difficult to establish effective 
treatments for the disease4. 
Radiation therapy and radioresistance in HCC patients 
HCC patients who are not candidates for surgical resection of tumors, constituting some 85% of 
the patient population, have various other options: radiation therapy, radiofrequency ablation, 
percutaneous ethanol injection, microwave coagulation therapy, and transarterial 
chemoembolization (TACE). For many years, clinicians were cautious to use radiation therapy 
due to the risk of inducing radiation-induced liver disease, which can eventually lead to liver 
failure. The risk of causing radiation-induced damage to nearby, uninvolved organs was also 
present. Radiation therapy given in low doses (ranging from 8 to 50 Gy) originally played a 
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larger role in improving symptoms for patients in palliative care by treating lymph node, bone, 
and brain metastases from primary HCC tumors. However, advances in imaging and delivery of 
radiation therapy have increased the use of radiation therapy in the last twenty years for both 
advanced and metastatic HCC patients. Combination of radiation therapy with TACE has been 
suggested to improve 5-year survival and reduce recurrence rates following treatment5. 
There are a number of methods of radiation delivery for HCC patients with varying overall 
survival and recurrence rates. A 2012 Swiss study with a cohort of 138 patients assessed the 
effectiveness of volumetric modulated arc therapy (VMAT) on modest tumor size. They report 
the mean survival for HCC patients treated at 45, 60, and 66 Gy were 8.6, 13.5, and 25.9 months, 
respectively, indicating effectiveness of radiation therapy increases in a dose-dependent manner. 
However, complete response to radiation therapy was achieved in only 11% of the patients, 
indicating resistance to treatment6. Three-dimensional conformal radiotherapy (3DCRT) is 
another form of radiotherapy that has found promising results. In a French phase II clinical trial, 
80% of patients treated with 3DCRT at 66 Gy were reported to have a complete tumor response. 
Although the data is encouraging, 22% of internal lesions and 41% of external lesions were 
recurrent after a mean follow-up of 29 months7. Furthermore, a metanalysis of clinical trials 
using either stereotactic body radiotherapy, radiofrequency ablation, and TACE showed that the 
highest 1-year overall survival for patients was 82%, while 1-year localized control varied 
anywhere from 65 to 100%8. 
The conflicting results from studies on treating HCC patients with radiation therapy make it 
evident that investigating the molecular mechanisms leading to radioresistance of HCC tumors is 
crucial for improving patient overall survival and reducing tumor recurrence. The identification 
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and subsequent targeting of a biomolecule involved in tumor radioresistance is a promising 
method of sensitizing HCC tumors to radiation treatment. 
AEG-1 structure and function 
Astrocyte elevated gene-1 (AEG-1), also known as MTDH or LYRIC, is an oncogene that was 
initially cloned in primary human fetal astrocytes9,10. The AEG-1 locus is present on human 
chromosome 8q22 and contains 12 exons and 11 introns11. AEG-1, which acts as a scaffolding 
protein, contains 582 amino acids, with a 51-72 amino acid single-pass transmembrane domain, 
and lacks identifiable functional or DNA-binding domains. However, an LXXLL motif present 
in its N-terminal domain interacts with transcriptional coactivators and co-repressors, indicating 
its function as a scaffolding protein12. All tissues ubiquitously express AEG-1 mRNA, although 
skeletal muscle, heart, and endocrine gland tissues have higher basal expression13. AEG-1 is 
expressed at low levels in wildtype hepatocytes, and is localized to the nucleus in these cells14. In 
transformed HCC cells, AEG-1 is localized to the cellular perinuclear space. When stimulated by 
TNF-α - an activator of the MAP kinase cascade and NF-κB survival pathways - AEG-1 
translocates to the nucleus to act as a potential transcriptional co-activator of the CREB-binding 
protein and NF-κB transcriptional complex15. 
Overexpression of AEG-1 has been indicated in multiple cancer types, including HCC, breast, 
prostate, non-small cell lung, and colorectal cancers16. AEG-1 overexpression in HCC was 
established by immunostaining using anti-AEG-1 antibody and by microarray of patient HCC 
liver samples. Primary HCC liver samples show increased AEG-1 staining when compared with 
normal adjacent liver samples, and HCV-associated HCC tissues show a marked increase of 
AEG-1 mRNA expression in contrast with normal and cirrhotic liver tissues.  HCC-derived cell 
lines have also been clearly characterized with AEG-1 overexpression. In vivo siRNA-mediated 
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downregulation of AEG-1 significantly suppresses the growth of xenografted HCC-derived 
tumors11. AEG-1 knockout mice lack spontaneous liver tumor formation throughout their 
lifespan, and treatment of AEG-1 knockout mice with diethylnitrosamine results in high 
resistance to tumor formation compared to wildtype mice, further establishing AEG-1’s role in 
liver carcinogenesis17. Analysis of patient HCC tissue samples corroborate in vitro and in vivo 
studies by demonstrating a marked increase of AEG-1 mRNA and protein expression; 
furthermore, AEG-1 expression levels in patients correlate with the stage and differentiation of 
HCC11. Clearly, AEG-1 can be used as a diagnostic and prognostic marker, and as a potential 
therapeutic target, in HCC. 
AEG-1 promotes cancerous phenotypes through activation of several intracellular signaling 
pathways. Hepatocytes derived from AEG-1 knockout mice show low activation of NF-κB, 
indicating that AEG-1 is required for NF-κB activation17. In vitro upregulation of AEG-1 
increases the migration and invasive profiles of HeLa and human glioma cell lines via activation 
of the NF-κB pathway, while siRNA-mediated downregulation of AEG-1 or of NF-κB decreases 
these characteristics15.  
The Ras-Raf-MEK-ERK pathway, which regulates cell proliferation and growth in response to 
extracellular signals such as mitogens, has also been indicated as a target for activation by AEG-
1. In AEG-1 overexpression clones, phosphorylated ERK42/44, p38 MAPK, and AKT 
expression was significantly increased, although there was no change in phosphorylation of the 
pro-apoptotic kinase JNK. Inhibition of ERK42/44 and p38 MAPK decreased in vitro matrigel 
invasion of AEG-1 overexpression clones, but did not significantly affect proliferation11. Akt, 
ERK1/2, and β-catenin are not regulated by AEG-1 as evidenced by a lack of difference in their 
phosphorylated forms between AEG-1 KO and wildtype mice17. These studies show the role of 
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AEG-1 overexpression in promoting an aggressive cancerous phenotype by inducing invasive, 
proliferative, and anchorage-independent growth characteristics, and by inhibiting pro-apoptotic 
signaling. 
Interestingly, AEG-1 has also been implicated in inhibiting senescence and dampening activation 
of the DNA damage response (DDR) in hepatocytes. In a transgenic mouse model with 
hepatocyte-specific expression of AEG-1, Srivastava et al. (2012) found that there was an 
increased number of cells positive for b-galactosidase – a marker for senescence – in cultured 
wildtype hepatocytes when compared to AEG-1 expressing hepatocytes. Subsequent protein 
expression analysis of the DNA damage markers ataxia telangiectasia mutated (ATM) protein, 
ATM and Rad3-related (ATR) protein, Chk1, and Chk2 demonstrated increased phosphorylation 
of these proteins in the wildtype hepatocytes compared against AEG-1 overexpressing 
hepatocytes. Therefore, AEG-1 expression may protect transformed hepatocytes from DDR-
induced senescence12. There have not yet been follow-up studies to elucidate the mechanism 
through which AEG-1 may directly or indirectly interact with the DDR signaling network. 
Regardless, it is evident that AEG-1 has diverse roles in initiating hepatocarcinogenesis and 
protecting transformed hepatic cells from cell death. 
The Mammalian Cell Cycle 
Eukaryotic cells can be in a dividing or non-dividing state. The non-dividing states include 
quiescence, senescence, differentiation, and apoptosis. Quiescence is reversible - after receiving 
mitogenic signals, such as cyclins D and E to de-repress E2F-dependent genes, quiescent cells 
can re-enter the cell cycle. Differentiated and senescent cells, on the other hand, are permanently 
withdrawn from the cell cycle. The genes involved in quiescence are a different subset of genes 
compared to those upregulated during growth or apoptotic inhibition18. 
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Cyclin dependent kinases (Cdk’s) interact with various protein cyclins to temporally regulate the 
phases of the cell cycle. The activity of these Cdk’s oscillate throughout the cell cycle and each 
cell cycle phase involves formation of specific Cdk-cyclin complexes. Cdk’s regulate cell cycle 
progression by binding various cyclins, including cyclins A, B, D, and E. Early G1 is regulated 
by the cyclin D/cdk4 and cyclin D/cdk6 complexes, while S-phase initiation is regulated by 
cyclins A and E expression19,20. The activated cyclin D/Cdk4/6 complex targets retinoblastoma 
protein, pRb, whose phosphorylation results in progression through G1. Following 
phosphorylation, pRb releases transcription factors of the E2F family, which activates cyclin E 
transcription. Cyclin E can then form a complex with Cdk2 to further phosphorylate pRb and 
promote G1 progression and S-phase entry21. 
Entry into G2/M is regulated by a phosphorylation switch of Cdk/cyclin complexes. Protein 
phosphatase 2A (PP2A) prevents entry into mitosis by dephosphorylating mitotic Cdk’s, and its 
activity is downregulated in multiple cancer types. Cdc25 activates Cdc2-cyclin B which 
promotes entry into M phase22. Cancer cells with defective G1/S checkpoints may rely on the 
G2/M checkpoint to avoid apoptosis and continue cell proliferation23. 
G0/G1 and G1/S checkpoints prevent inappropriate DNA replication, while G2/M checkpoint 
allows for DNA repair. Two families of Cdk inhibitors negatively regulate the cell cycle: the 
INK family binds cdk4 and cdk6 to inhibit D-type cyclin/cdk complex formation; and p21 which 
inhibits kinase activity by binding cyclin/Cdk complexes. p21 can therefore inhibit cell cycle 
progression at the G1/S boundary24. 
The DNA Damage Response 
DNA damage may result from a variety of intracellular and extracellular stimuli, and if not 
resolved, may lead to genomic instability. Ionizing radiation (IR) is one such inducer of DNA 
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damage. The effects of IR can either be direct (i.e. DNA double-stranded breaks) or indirect 
(formation of reactive oxygen and reactive nitrogen species). ROS and RNS can induce single-
stranded DNA breaks (SSB’s) and double-stranded DNA breaks (DSB’s), DNA crosslinks, and 
base damage. Surviving cells after IR will have progeny that are characterized by chromosomal 
rearrangements, aneuploidy, gene amplification, altered gene expression, and other 
characteristics of genetic instability25. Cells exposed to IR during S-phase are susceptible to 
replication fork stalling and collapse, base mispairing, and point mutations. On the other hand, 
IR exposure during mitosis can lead to loss of genetic material and cell death21. 
Genomic instability can predispose a cell to initiating carcinogenesis. Homologous 
recombination repair (HRR) and non-homologous end joining (NHEJ) are two repair pathways 
present in mammalian cells that protect genomic integrity in the presence of genotoxic stressors. 
While NHEJ repairs blunt DNA breaks without sequence homology, HRR restores double-
stranded breaks and requires sequence homology in the form of a sister chromatid as a template. 
HRR can only occur in S and G2 phases due to the availability of CDK1, which is needed for 5’-
3’ end processing and DNA synthesis recovery. NHEJ, on the other hand, can occur throughout 
the cell cycle. Although the DNA repair pathways are compartmentalized to facilitate our 
understanding of their mechanisms, there is likely crosstalk between the pathways. They can 
complement, counteract, or overlap each other’s functions26. 
HRR recruits a multitude of proteins to repair DSB’s. Following generation of a DSB, resection 
of the 5’ end creates a 3’ single-stranded on each side of the DSB. Replication protein A (RPA) 
coats the exposed single-stranded DNA (ssDNA), and is then replaced by Rad51 in a Rad54, 
PALB2, BRCA2-dependent process. Strand invasion from the sister chromatid then occurs to 
create a Holliday Junction. Cohesin proteins stabilize the strand invasion complex and promote 
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faithful HRR. DNA replication then ensues using the undamaged chromatid as a template27. 
When HRR is insufficient in cells or if the number of DSB’s is too large for the cell to repair, the 
cells are directed to apoptosis28. 
In response to IR, ATM phosphorylates Mdm2/p53 and Chk2. Stabilization of p53 and its 
subsequent transactivation of p21 is the slow (2-3 hour) response following IR and results in 
inhibitory binding of both cyclin D/Cdk4/6 and cyclin E/Cdk2 complexes. Chk2 activation, on 
the other hand, occurs much faster (<1 hour) and results in inactivation of Cdc25, which also 
results in inhibitory phosphorylation of the cyclin E/Cdk2 complex21. 
ATR is recruited to stalled replication forks and single-stranded DNA breaks by ATR-interacting 
protein (ATRIP), which interacts with RPA-bound ssDNA via its acidic checkpoint recruitment 
domain. The 9-1-1 complex - consisting of RAD9A, RAD9B, HUS1, and RAD1 – along with 
DNA topoisomerase 2-binding protein (TOPBP1) are recruited to the single-stranded breaks. 
TOPBP1 phosphorylates and activates ATR, which induces ATR’s kinase activity. 
Subsequently, ATR activates Chk1 via phosphorylation and inactivates CDK1/2 activity29,30. 
Breast cancer type 1 and 2 susceptibility proteins (BRCA1 and BRCA2) function in DSB repair 
and control mitotic entry in the presence of DNA damage via control of the G2 checkpoint31. 
BRCA1 coordinates MRN and CtIP complex formation, while BRCA2 stabilizes Rad51 
filaments26. 
PARP1 is another prominent player in NHEJ, HRR, and base mismatch repair pathways. Briefly, 
PARP1 senses DSB’s and quickly recruits meiotic recombination 11 (MRE11) and Nijmegen 
breakage syndrome 1 (NBS1) proteins to those sites. Once bound to sites of DNA damage, 
PARP1 catalyzes the addition of poly(ADP-ribose) chains to itself in addition to DNA repair 
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enzymes and histones, and then recruits repair factors29. There is evidence that when PARP1 is 
unavailable, single-stranded DNA breaks lead to stalled replication forks, which are then 
converted to double-stranded breaks to be repaired by HRR32. However, elimination of PARP1 
does not completely prevent activation of the DDR, suggesting that its role is redundant in these 
complex pathways33. 
TP53 is a tumor suppressor gene that acts as a central hub for numerous cellular processes, 
including those controlling apoptosis, growth arrest, cell cycle progression, and DNA repair. The 
protein product of TP53, p53, is coined the “guardian of the genome” due to its ability to induce 
G1 arrest following DNA damage34. It is hypothesized that p53 mutation status determines the 
survival fate of cells facing large amounts of DNA damage, while cells with smaller amounts of 
DNA damage are able to appropriately repair DNA damage and begin cycling normally again. 
Therefore, coordinating multiple signaling pathways is needed to decide whether a cell will 
increase its DNA repair and survival response, or induce apoptosis, in response to ionizing 
radiation35,36. 
BCCIP structure and function, and AEG-1 interaction 
BRCA2-and-p21-interacting protein (BCCIP) acts as a tumor suppressor gene and has been 
shown to have a role in the DNA damage response during homologous recombination repair of 
double-stranded DNA breaks in conjunction with BRCA2. BCCIP also promotes cell cycle arrest 
at the G1/S checkpoint by enhancing the inhibition of CDK2 activity via binding of 
CDKN1A/p21. Two isoforms of BCCIP exist in humans, BCCIPα and β, which contain identical 
N-terminal domains and differ in their C-termini. Both isoforms are localized to the nucleus and 
are ubiquitously expressed across skeletal muscle, heart, kidney, and brain tissues, among others. 
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At the G1/S checkpoint and throughout S phase, both BCCIPα and BCCIPβ mRNA expression 
peak. However, BCCIP’s role in interacting with p21 to promote cell cycle arrest is primarily 
attributed to the α isoform37. 
The clinical significance of BCCIP expression has been investigated in several human cancers, 
including downregulation of both isoforms in multiple human kidney tumors38. In HCC, BCCIP 
downregulation correlates with reduced survival, increased tumor size, and higher histological 
grade of tumor in patients. Furthermore, in vitro knockdown of BCCIP in human-derived 
hepatocytes promotes cell proliferation, confirmed by accelerated G1 to S transition in these 
cells39. This suggests an inability of BCCIP to act in the DNA damage response and allow for 
cell survival despite genetic instability in an HCC model. 
In the cell cycle, BCCIP is an upstream regulator of the p53/p21 pathway of G1/S checkpoint 
inhibition. BCCIPα acts as an upstream regulator of p53 by inducing p53 upregulation, which 
subsequently increases p21 expression. In a human fibrosarcoma cell line, downregulation of 
BCCIPα (RNAi-BCCIPα) impairs the G1/S checkpoint. Furthermore, ionizing radiation of the 
RNAi-BCCIPα cell line with γ-rays at 10 Gy results in hastened progression through G1 and S 
phases, while cell lines with normal basal expression of BCCIPα are blocked in G1. 
Downregulation of p21 at the protein and mRNA levels in RNAi-BCCIPα cell line indicates 
BCCIPα downregulation may lead to a lack of CDK2 inhibition in response to DNA damage40. 
Recently, BCCIP has also been identified as a regulator of mitotic spindle integrity through the 
C-terminus of BCCIPb localizing to spindle poles and both of its isoforms interacting with 
dynein and dynactin; however, this function appears to be independent of its function in the 
DNA-damage-response41. 
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There is strong evidence suggesting BCCIP’s role in the HRR pathway. Radiation-induced 
RAD51 foci colocalize with BCCIP in HRR. BCCIP and BRCA2 foci also co-localize in the 
nucleus in an ionizing-radiation-independent manner, although there is no increase in BCCIP 
foci in response to ionizing radiation. RAD51 foci co-localization with BCCIP occurs in a dose-
dependent manner of ionizing radiation. This suggests RAD51 foci co-localization, but not 
BRCA2 foci co-localization, with BCCIP is involved in the DNA damage response in response 
to ionizing radiation. Subsequent downregulation of BCCIP results in decreased formation of 
RAD51 and BRCA2 foci42. Furthermore, BCCIP suppression increases spontaneous single-
stranded and double-stranded DNA breaks in the absence of ionizing radiation43. 
There is some preliminary research on the interaction between AEG-1 and BCCIP. In prostate 
tumor cells, co-transfection of AEG-1 and BCCIPα in a yeast two-hybrid system demonstrate a 
decrease in BCCIPα protein levels, and overexpression of AEG-1 induces proteasomal 
degradation of BCCIPα. Proteasomal-mediated-downregulation of BCCIPα protein levels was 
shown to depend on presence of the intact NH2-terminal domain of AEG-1, as demonstrated by 
flag-tagged constructs with sequence deletions of AEG-144. However, it is unknown if BCCIPα 
directly binds the NH2-terminal domain of AEG-1, or if BCCIPα degradation is a consequence 
of downstream activity mediated by the amino terminus binding to other signaling molecules. 
Due to the role of BCCIPα in the DNA damage response, and due to its interaction with AEG-1, 
further studies delineating the potential role of AEG-1 in the DNA damage response can help us 
better understand how HCC cells are able to overpass cell cycle checkpoints and continue 
replicating their genomes despite exogenous DNA damage. Therefore, this may clue us into a 
mechanism of radioresistance that occurs in HCC.  
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CHAPTER 2 
MATERIALS AND METHODS 
Generation of AEG-1 knockout (KO) cell lines 
The DihXY cell line is a diethylnitrosamine-induced HCC mouse hepatic cell line. The cell line 
was generously provided by Dr. Michael Karin's laboratory. 
The QGY-7703 cell line was derived from a 30 year-old female human patient with aggressive 
HCC. QGY-7703 cells also express AEG-1 at very high levels11. The cell line was obtained from 
Fudan University, Shanghai, China. 
The HuH7 cell line is a human-derived, well-differentiated hepatic cell line that was originally 
obtained from a 57 year-old male with HCC. The cell line was generously provided by Dr. Paul 
Dent’s laboratory. 
AEG-1 knockout was attained in each of the above cell lines using the Crispr/Cas9 system. The 
cloning vector was obtained from GeneCopoeia. The sgRNA targeted MTDH at the sequence 
GACTTCAACAGTCCGCCCATT. The vector contained either puromycin or ampicillin 
resistance genes with a selective mCherry marker. Cells were pulsed using the Gene Pulser Xcell 
unit and then seeded at a density of 5 x 106 in 6-well plates. Single clones were isolated and 
expanded using FACS-sorting for mCherry positive cells. For the DihXY cell line, a single 
AEG-1 knockout clone (DihXY-A8) was used for subsequent studies. For the QGY-7703 cell 
line, an AEG-1 knockout clone (QGY-A3), a partial knockout clone (QGY-A7) and a negative 
clone (QGY-A26) were used for subsequent studies. For the HuH7 cell line, two knockout cell 
lines (HuH7-A1 and HuH7-A6) and two negative cell lines (HuH7-A5 and HuH7-A12) were 
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used for initial characterization of the cell lines. The HuH7-A6 and HuH7-A12 cell lines were 
subsequently selected for radiation studies. 
Cell culture conditions 
HuH7 and QGY-7703 cell lines were grown in Dulbecco’s Modified Eagle Media (DMEM) 
containing 10% (v/v) fetal bovine serum (FBS), 1% penicillin/streptomycin (PenStrep), and 
.025% ciprofloxacin. DihXY cell line was grown in DMEM containing 20% FBS, 1% PenStrep, 
.025% ciprofloxacin; and containing 0.12g phenobarbital, 20μL mouse epidermal growth factor 
(0.5μg/μL solution), 0.005g hydrocortisone, and 0.5mL insulin per 500mL of media. All cell 
lines were tested for mycoplasma-free status using a Mycoplasma Detection Kit (Thermo Fisher 
Scientific). Cell lines were used for a maximum of 10 passages, and maintained at 37oC in a 
humidified atmosphere containing 5% CO2. 
Radiation treatment 
For cells treated with radiation, they were subjected to ionizing radiation at a dose rate of 1-2 
Gy/minute. DihXY cells were treated with 2.5, 5.0, and 10.0Gy; while QGY-7703 and HuH7 
cells were treated at 2.5 and 10Gy. 
Colony formation assay 
500 cells were plated in 6cm dishes in triplicates per condition. For cells treated with ionizing 
radiation or sorafenib, cells were plated at least 6 hours prior to treatment in order to allow cells 
to adhere. Media was replaced every 4 to 5 days. 13 days after plating, cells were fixed with 10% 
formaldehyde, gently rinsed with DI water and then incubated with a 25% working Giemsa 
solution. After 1-hour incubation in stain, cells were rinsed thrice gently with DI water. 
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MTT assay 
2000 cells per well were seeded in 96-well plates and incubated in a 10% (3-(4,5-
Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) (MTT) solution for 4 hours at either 
24, 48, 72 hours, or at 48, 96, 144 hours post-seeding. Following incubation in MTT, 10% 
sodium dodecyl sulfate (SDS) solution was added to cells. After incubating cells overnight, 
absorbance was measured at 600nm using a GloMax microplate reader. For cells that received 
sorafenib treatment, cells were seeded at the above density and allowed to adhere for 6 hours 
prior to sorafenib treatment. For irradiated cells, cells were first plated in 6cm dishes and then 
trypsinized and seeded in the 96-well plate following radiation. 
Flow cytometry 
To assess cell cycle progression in untreated QGY-7703, HuH7, and DihXYXY cells, cells were 
synchronized using a double thymidine block to accumulate cells at the G1/S border and 
subsequently released into S-phase. Thymidine was purchased from Sigma-Aldrich (catalog # 
T1895). Cells were plated at a density of 2.5 x 105 cells in 10cm dishes. 200mM thymidine 
solution was added to cell culture media to a final concentration of 2mM. Cells were first 
blocked for 18 hours; then released with fresh DMEM for 9 hours; and blocked a second time for 
17 hours. Following release with fresh DMEM from the second block, cells then fixed with cold 
70% EtOH, treated with 100μg/mL RNase (purchased from Invitrogen) and stained with 1.0 
mg/mL propidium iodide solution (purchased from Sigma Aldrich, catalog #P4864) overnight at 
4oC prior to data acquisition. 
For DihXY cells treated with radiation, cells were plated at a density of 2.5 x 105 in 10cm dishes 
at least 6 hours prior to treatment. For FACS collection, cells were fixed with cold 70% EtOH, 
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treated with 100μg/mL RNase and stained with propidium iodide overnight at 4oC prior to data 
acquisition. 
For QGY-7703 and HuH7 treated with radiation, cells were plated at a density of 2.5 x 105 cells 
in 10cm dishes at least 6 hours prior to treatment. The FITC BrdU Flow Kit (purchased from BD 
Biosciences, catalog #559619) was used to double-stain samples with 7-AAD and BrdU. 
Following radiation, HuH7 cells were pulsed with 1mM BrdU solution for 30 minutes (BrdU 
incubation time was optimized in untreated HuH7 cells). Cells were then washed with DPBS and 
fresh media was added. Cells were fixed and stained with anti-BrdU and 7-AAD per the staining 
kit protocol. Briefly, cells were trypsinized, treated with Cytofix/Cytoperm Buffer for 20 minutes 
at room temperature, treated with Cytoperm Permeabilization Buffer Plus for 10 minutes on ice, 
and treated a second time with Cytofix/Cytoperm Buffer for 5 minutes on ice. Cells were then 
treated with DNase for 1 hour at 37oC, stained with anti-BrdU for 20 minutes, and then stained 
with 7-AAD overnight at 4oC prior to data acquisition. Negative controls were cells pulsed with 
BrdU and either 1) stained with neither anti-BrdU nor 7-AAD; 2) stained with anti-BrdU; or 3) 
stained with 7-AAD. 
For QGY-7703 cells, cells were collected at 30 minutes post-radiation or post-double-thymidine-
block and subsequently every 4 hours for 12 hours. For HuH7 cells, cells were collected at 30 
minutes and subsequently every 6 hours for 48 hours. For  cells, cells were collected at 30 
minutes and subsequently every 4 hours for 24 hours. 
BD FACSCanto™ II Analyzer and FACSDIVA software at the VCU Flow Cytometry Shared 
Resource Core was utilized to acquire and analyze data. Flow cytometry data was analyzed using 
FlowJo data analysis software. 
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Immunohistochemistry 
Immunohistochemistry was used to analyze BCCIP expression in previously obtained Cre/lox 
AEG-1 knockout, and wiltype AEG-1, hepatic tissues of C57BL/6 mice45. Briefly, paraffin-
embedded tissues were fixed to glass slides and incubated at 60 oC for one hour. Slides were then 
incubated in xylene twice to de-paraffin the tissues. 100%, 90%, 80%, and 70% EtOH were used 
to rehydrate the tissues. Subsequently, tissues were incubated in water and PBS for 5 minutes 
each. Antigen retrieval buffer was applied to the tissues for 10 minutes in microwave, and then 
rinsed with PBS. 2% hydrogen peroxide was used to quench endogenous hydrogen peroxidase 
for 20 minutes, and then rinsed with PBS. Slides were blocked in 5% goat serum for 1 hour at 
room temperature. Slides were incubated in primary antibodies (AEG-1 and BCCIP) overnight at 
4oC. Slides were rinsed with PBST thrice for 5 minutes, and then incubated in biotinylated 
secondary antibody for 1 hour at room temperature. Following secondary antibody incubation, 
slides were washed thrice for 5 minutes, and then incubated in ABC reagent for 30 minutes at 
room temperature. Slides were again rinsed thrice with PBST for 5 minutes. Slides were 
incubated in DAB substrate for 1-5 minutes, then rinsed in water and incubated in hematoxylin 
for 20 seconds. After rinsing with water, tissues were dehydrated using gradient EtOH, cleaned 
with xylene, and slides were mounted with permount. 
Immunofluorescence 
Cells were seeded at a density of 2.5 x 104 cells/mL in Millicell EZ slides (Millipore). For cells 
treated with ionizing radiation, cells were allowed at least 6 hours to adhere prior to treatment. 
To fix cells, 4% paraformaldehyde was used and then washed thrice with DPBS. Cells were then 
permeabilized with 0.1% triton solution and washed thrice with DPBS. A 1% bovine serum 
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albumin, 10% goat serum in 10x PBS solution was used to block cells for 2 hours at room 
temperature. Following blocking, cells were treated with primary antibody overnight at 4oC. 
Cells were washed with DPBS and then incubated with a 1:400 dilution of fluorochrome 
conjugated secondary antibodies in blocking buffer for 1 hour at room temperature. Cells were 
then washed with DPBS and mounted with DAPI. Negative controls used in this assay were cells 
incubated with primary antibody, but no secondary antibody. Antibodies used were BCCIP 
(ProteinTech #16043-1-AP), γ-H2AX (Cell Signaling #9718) and AEG-1. Images were acquired 
using a Zeiss LSM confocal microscopy at a magnification of 63x at the VCU Microscopy Core, 
and quantified using ImageJ. 
In vitro wound healing assay 
2-well silicone inserts were purchased from Ibidi (catalog #80209) to assess cell migration. 70μL 
of a 5 x 105 cells/mL suspension was added to each side of the well, one insert per well in 12-
well plates. Cells were allowed to adhere overnight. The insert was removed, which created a 
500μM lesion, and fresh media was added to each well. The resulting lesion was imaged at 0, 24, 
and 48 hours following removal of the insert. Images were obtained with at 4x and 10x 
magnification. Lesion sizes at 10x magnification at each time point were quantified using the 
MetaVi Labs online automated cellular analysis system. 
Invasion assay 
BioCoat™ Matrigel® Invasion Chambers were purchased from Corning. Serum-free DMEM 
containing 0% FBS was used to rehydrate the inserts for 2 hours at 37oC and 5% CO2. 750μL of 
DMEM containing 10% FBS was added to each well in a 24-well plate. Inserts were placed in 
each well, and 2.5 x 104 cells suspended in 500μL serum-free DMEM were added to each insert. 
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The cells were incubated for 22 hours at 37oC and 5% CO2. Following incubation, DMEM-
moistened cotton swabs were used to gently remove non-invasive cells from the inserts. The 
inserts were then fixed and stained with a Diff-Quik staining kit. Images of the invading cells 
were taken at 10x magnification. The number of invading cells per field were counted manually. 
Western blotting 
Cells to be collected for total protein lysate were seeded at a density of 1.0 x 106 in a 6cm dish. 
Cells were then washed with DPBS twice and treated with 1.5% n-dodecyl-D-maltoside (DDM) 
lysis buffer containing PhosStop Easypack phosphatase inhibitor cocktail tablets (Roche) and 
cOmplete Mini protease inhibitor cocktail tablets (Roche). After lysis, cells were centrifuged at 
15000 RPM for 15 minutes. Supernatant was carefully removed and protein concentration was 
measured using Bradford assay. 20μg to 40μg of protein lysate was resolved in 8 to 12% SDS-
PAGE and then transferred on nitrocellulose membranes. Following transfer, cells were blocked 
in 5% nonfat milk in TBST solution for 1 hour. For primary antibodies to be incubated in bovine 
serum albumin, membranes were washed 3 x 5 minutes with TBST prior to adding antibody. All 
membranes were incubated overnight at 4oC. Prior to secondary antibody incubation, cells were 
washed 3 x10 minutes with TBST. Secondary antibodies were applied for 1 hour at room 
temperature. Membranes were washed again 3 x 10 minutes with TBST. Chemiluminescence 
detection reagents were applied to membranes and images of the proteins were obtained on 
autoradiography films. EF1α or GAPDH were used as internal controls. Western blot images 
were quantified using ImageJ. 
List of antibodies used: 
• Cyclin D1 Cell Signaling #2978 • BCCIP ProteinTech 16043-1-AP 
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• p21 Cell Signaling #2947 
• Phospho-ATR (Ser428) Cell 
Signaling #2853 
• Phospho-BRCA1 (Ser1524) Cell 
Signaling #9009 
• GAPDH Santa-Cruz sc-166545 
• Phospho-Chk2 (Thr68) Cell 
Signaling #2197 
• Phospho-Chk1 (Ser345) Cell 
Signaling #2348 
• Chk1 Cell Signaling #2360 
• Chk2 Cell Signaling #2662 
• p53 Cell Signaling #2527 
• gH2AX (Ser139) Cell Signaling 
#9718 
• Phospho-p53 (Ser15) Cell Signaling 
#9286 
• Phospho-ATM (Ser1981) Cell 
Signaling #5883 
• ATM Cell Signaling #2873 
• ATR Cell Signaling #13934 
• AEG-1 
• EF1α Millipore 05-235 
• Cyclin E Santa-Cruz sc-481 
Statistical analyses 
Significance of results was tested using student paired T-test with two-tailed hypothesis. 
Statistical significance for all data was considered to be a P value of <0.05.  
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CHAPTER 3 
RESULTS 
Knockout of AEG-1 using Crispr-Cas9 reduces cell proliferation in HCC cells 
AEG-1 knockout was previously achieved in the DihXY cell line46, and for this study, was 
successfully replicated in the QGY-7703 and HuH7 cell lines using the Crispr-Cas9 vector. A 
single knockout and negative (wildtype AEG-1) clone were selected from the HuH7 and QGY-
7703 cell lines, along with a partial knockout clone in the QGY-7703 cell line. A negative clone 
was not available in the DihXY cell line, so the parental cell line was used for AEG-1 WT 
characterization. AEG-1 expression was confirmed in the knockout and negative HuH7 and 
QGY-7703 cell lines using western blotting (Fig. 1A). The AEG-1 WT and KO cell lines were 
initially characterized for cell survival and cell viability. Significantly fewer colonies formed in 
the AEG-1 KO cell line compared to the AEG-1 WT and partial KO cell lines in the QGY-7703 
cell line (Fig. 1B, P-values 0.0425 and 0.0163, respectively). However, there was no significant 
difference in colony formation in the HuH7 cell lines (Fig. 1E). In the MTT assay, QGY-7703 
AEG-1 KO cells showed significantly reduced proliferation compared to AEG-1 WT cells at 24-, 
48-, and 72-hour time-points (P-values 0.00014, <0.00001, and 0.00024, respectively). When the 
percent cell viability of QGY-7703 AEG-1 KO cells was normalized against AEG-1 WT cells, 
the AEG-1 KO cells only proliferated up to 78% that of the AEG-1 WT cell line, and did not 
show exponential growth (Fig. 1C). On the other hand, the HuH7 AEG-1 KO cell line had 
increased cell viability at all time-points in the MTT assay (Fig. 1D). When the percent cell 
viability of HuH7 AEG-1 WT cells were normalized against AEG-1 KO cells, the WT cells 
showed a sharp increase in proliferation after 3 days of incubation. The WT cells continued to 
increase until they reached 82.5% cell viability of the KO cells after 8 days of incubation. 
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Knockout of AEG-1 results in decelerated cell cycle progression 
After observing the phenotypic effect of AEG-1 knockout in cell proliferation, we sought to 
characterize the cell cycle profiles of AEG-1 WT and KO cell lines. Although all cell lines 
demonstrated marked cell cycle acceleration (Fig. 2A-D), this was more apparent in the QGY-
7703 WT cells compared to the DihXY cells or HuH7 cells. 
Three independent cell cycle experiments were performed on untreated, QGY-7703 cells that 
were synchronized into the G1/S boundary using a double thymidine block, and subsequently 
stained with either PI or 7-AAD. For each experiment, 20,000 cellular events were recorded 
during FACS data acquisition. Cells were gated into G1/G0, S, and G2/M and a percentage of 
cells in each phase was calculated. These percentages from each independent experiment were 
averaged and standard deviation error was calculated to determine the reliability of our methods 
(Fig. 2A). The figure shows that we were able to consistently synchronize the cells into the G1/S 
boundary and release into S-phase. Furthermore, our results also show that the QGY-7703 cell 
lines maintain a routine pattern of accumulating in G0/G1 after 12 hours, with the AEG-1 WT 
cells proceeding more rapidly than the AEG-1 KO cells. Although the error bars are not tight, we 
argue that this is because the mean and standard deviation were calculated from three data-
points, while each of these data-points contained at least 20,000 cellular events. Therefore, we 
can reliably use this method of analyzing cell cycle progression for our project. 
DihXY AEG-1 WT and KO cells were released into S-phase (42.3% and 51.2%, respectively) 
following double-thymidine block (Fig. 2B). Both KO (55%) and WT (53.1%) cells are 
maximally in G2/M after 4 hours and complete a round of replication after 8 hours. After 24 
hours, KO (72.4%) and WT (47.5%) cells are maximally in G1/G0 once more, completing a 
second round of replication. However, at 24 hours, WT cells are entering S- (21.7%) and G2/M 
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(30.7%) phases, while KO cells remain accumulated in G1/G0 (S-phase cells 14.5%, G2/M cells 
13.2%), indicating the WT cells are entering a third round of replication more rapidly than KO 
cells. 
Following release of QGY-7703 cells from a double-thymidine block, AEG-1 WT and KO cells 
were accumulated in S-phase (69.6% and 69.3%, respectively; Fig. 2C). After 4 hours, WT cells 
accumulated in G1/G0 (75.4%), while KO cells were still cycling in S (49.5%) and G2/M (39%), 
indicating WT cells had successfully completed replication. KO cells do not accumulate in 
G1/G0 (70.3%) until 12 hours post-release, at which time WT cells accumulate in G1/G0 again 
(81%) and have completed a second cycle of replication. 
HuH7 AEG-1 WT and KO cells were released into S-phase (59.4% and 73.2%, respectively) 
after a double-thymidine block (Fig. 2D). Both KO and WT cells complete their first round of 
replication after 18 hours (data not shown). After 24 hours, WT cells appear to complete a 
second cycle of replication, at which point they accumulate in G1/G0 (54.1%). At 12-, 24-, and 
36-hours post-release, HuH7 AEG-1 WT cells are accumulated in G1/G0 to a higher percent 
compared to HuH7 AEG-1 KO cells. 
Knockout of AEG-1 reduces migration and invasion in HCC cells 
To further characterize the effect of AEG-1 knockout in QGY-7703 cells, the Crispr/Cas9 
generated cell lines were assessed for their invasive and migratory capabilities. As previously 
described, AEG-1 has been well-studied in its role in upregulating various cell invasion and 
migration pathways, including NfkB, MMP2, and MMP9 signaling. Invasion assay using QGY-
7703 cells (Fig. 3A, top) showed a significantly increased number of invading cells per field in 
both the partial KO and WT AEG-1 cells, compared to the KO cells (P-values 0.00600 and 
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0.00596, respectively). Similarly, HuH7 cells assayed for invasive capacity (Fig. 3A, bottom) 
showed a significantly reduced number of invading cells in the AEG-1 KO cell line compared to 
AEG-1 WT cells (P-value 0.00068). In the wound healing assay (Fig. 3B, top), QGY-7703 
AEG-1 KO cells showed significantly reduced cell migration within 24 hours of creating the 
lesion (P-value 0.03968). However, both cell lines equally migrated after 48 hours. There was no 
significant difference in the initial lesion size (P-value 0.26529). 
In the HuH7 cell lines, A6 (AEG-1 KO) cells showed significantly reduced cell migration 
compared to the A5 and A12 (AEG-1 WT) cells after 48 hours (P-values 0.01760 and 0.02136, 
respectively; Fig. 3B, bottom). The initial lesion size between the A6 and A5/A12 cell lines were 
not significantly different (P-values 0.45298 and 0.89823, respectively). 
Knockout of AEG-1 sensitizes HCC cells to low-dose IR 
In QGY-7703 and HuH7 cell lines, AEG-1 KO cells were significantly sensitized to radiation 
treatment at 2.5 Gy (Fig. 4A and 4C, respectively). In QGY-7703 cells, P-value was 0.00633; in 
HuH7 cells, P-value was 0.02871. Although DihXY AEG-1 WT cells showed marked resistance 
to IR at 2.5 Gy, the results were not significant (Fig. 4B, P-value 0.05602). 
Negative and positive regulators of the G1/S transition are upregulated in AEG-1 WT QGY-7703 
cells following low-dose IR 
After observing sensitization of AEG-1 knockout cells to ionizing radiation, and the differences 
in cell cycle progression in the cell lines following IR, we decided to study protein expression of 
signaling molecules involved in the G1/S transition in both untreated cells and cells treated with 
low-dose IR (2.5 Gy). In QGY-7703 cells treated with 2.5 Gy, there was a 16.7% decrease from 
G1/G0 in WT cells between 4 to 8 hours, while only 4.8% decrease in KO cells. At 8 and 12 
hours, KO cells are 59.1% and 58.8% in S-phase, respectively; while WT cells are 30.8% and 
 25 
48% in S-phase, respectively (Fig. 5B). This correlates with a decrease in cyclin D1 expression 
in WT cells at 8 and 12 hours compared to KO cells after IR (Fig. 6C). p-p53 expression was 
consistently upregulated in WT cells at all time-points following IR at 2.5 Gy. Similarly, p21 
expression was upregulated in IR-treated WT cells at 8 hours. On the other hand, in KO cells 
treated with IR, p-p53 expression decreased at 30 minutes and 4 hours, while it remained 
unchanged at 8 and 12 hours. Interestingly, p21 expression was downregulated in IR-treated KO 
cells at 8 and 12 hours when compared to untreated KO cells (Fig. 6A). Total p53 expression in 
untreated QGY-7703 cells was greater in the AEG-1 WT cell line than in the KO cell line at 8 
and 12 hours (Fig. 6B). This observation correlates with greater p-p53 signaling at 8 and 12 
hours. When revisiting the cell cycle data, we observe that the untreated QGY-7703 AEG-1 KO 
and WT cells are maximally in G2/M at 8 hours, and re-entering G0/G1 at 12 hours post-
thymidine release (Fig. 2C), indicating p53 expression is transcriptionally activated when these 
cells are minimally in S-phase. Unexpectedly, bands for p53 were not visible in either WT or KO 
cells when irradiated at 2.5Gy. 
Cyclin D1 expression was increased in UT AEG-1 WT cells compared to AEG-1 KO cells; 
however, following IR at 2.5 Gy, AEG-1 KO cells showed increased cyclin D1 expression 
compared to AEG-1 WT cells (Fig. 6C). In both AEG-1 WT and KO cells, cyclin E expression 
was consistently upregulated after treatment at 2.5 Gy and 10Gy (Fig. 6C). At 30 minutes post-
2.5 Gy, cyclin E expression triples in KO cells, compared to untreated cells at the same time-
point; while expression in WT cells increases approximately 1.7-fold. At 4 hours post-2.5 Gy, 
cyclin E expression doubles in both KO and WT cells when compared to untreated cells at the 
same time-point; however, at 10Gy, expression in KO cells nearly triples, while in WT cells it 
only increases by about 2.5-fold. Cyclin E expression is reported to be highest during the G1/S 
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transition47; however, in both IR-treated KO and WT cells, cyclin E expression peaks at 8 and 12 
hours, while their cell cycle profiles show they are in majority S- or G2/M phase (Fig. 5B). 
Positive regulators of the G1/S transition are upregulated in AEG-1 WT HuH7 cells following IR 
In the irradiated HuH7 cells, both KO and WT cells had similar cell cycle profiles initially after 
radiation (KO = 49.6% and WT = 50.8% in G1/G0; Fig. 5A). At 12 and 24-hours post-2.5 Gy, 
there was a greater percentage of KO cells in G1/G0 than WT. At 24 hours, 24.9% WT cells 
were in G2/M, compared to only 18.2% of KO cells. After 12 hours, more WT cells have cycled 
into S (30.6%) and G2/M (34.8%), compared to KO cells (27.6% in S, 29.3% in G2/M). When 
analyzing protein expression of cell cycle regulators, we found that HuH7 AEG-1 WT cells 
showed increased expression of cyclin E initially (30 minutes) after thymidine release (Fig. 7B). 
Afterwards, cyclin E expression remained consistently higher in untreated KO cells when 
compared against untreated WT cells. This conflicts with the pattern of cyclin E expression in 
irradiated QGY-7703 cells (Fig. 6C), which showed increased expression in the untreated WT 
cells at all time-points except at 8 hours. In the HuH7 cells treated with 2.5Gy, cyclin E was 
initially upregulated in KO cells , while it was downregulated in the WT cells, when compared 
against their untreated counterparts. After 12 hours, cyclin E was downregulated in both WT and 
KO cells, although it was decreased approximately 50% in KO cells and 80% in WT cells. At 24 
hours following IR, cyclin E expression remained downregulated in KO cells, while its 
expression was increased in WT cells, compared to their untreated counterparts (Fig. 7B). This 
replicates a similar observation of cyclin E upregulation in irradiated QGY-7703 AEG-1 WT 
cells, although the QGY-7703 cells showed a more profound and consistent pattern of cyclin E 
upregulation (Fig. 6C). 
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Similar to QGY-7703 cells, p21 expression peaked in both HuH7 AEG-1 WT and KO cells at 
the last time-point following thymidine release (Fig. 7A), which correlates with WT cells 
accumulating in G1/G0 (Fig. 2D), but does not corroborate with our observation that KO cells 
accumulate in S-phase at that time-point (Fig. 2D). Unlike QGY-7703 cells, HuH7 AEG-1 WT 
cells did not appear to upregulate p21 expression to a higher degree than KO cells following IR 
at 2.5Gy (Fig. 7A). In the irradiated HuH7 cells, p21 expression appeared to decrease in AEG-1 
KO cells at the 12 and 36 hour time-points, which correlate with a lack of robust G1/G0 
accumulation at these time-points (Fig. 5A). On the other hand, irradiated AEG-1 WT cells did 
not show a change in p21 expression at the 12 hour time-point, but p21 expression was 
downregulated at 24 and 36 hours post-IR when compared to its untreated counterparts. 
AEG-1 KO results in delayed DSB signaling compared to AEG-1 WT cells following low-dose IR 
In the QGY-7703 cell lines, protein expression of the phosphorylated forms of the DNA double-
stranded break sensors ATR and ATM were more strongly upregulated in AEG-1 WT cells at 30 
minutes post-IR at 2.5Gy when compared to irradiated AEG-1 KO cells (Fig. 8A and 8C). This 
pattern of expression was consistent for p-ATR at all time-points following IR, but p-ATM 
expression had stronger expression in the AEG-1 KO cells starting at 8 hours post-IR at 2.5Gy. 
Although quantification of gH2AX expression against internal control showed higher expression 
in irradiated WT cells than irradiated KO cells at 30 minutes (Fig. 8C), the western blot images 
and IF imaging stained with the same gH2AX antibody (Fig. 11B-C) demonstrated increased 
signal in KO cells than in WT cells at this time-points. Notably, p-ATR – which has a stronger 
role in sensing single-stranded DNA breaks and stalled replication forks (reviewed in Haynes, 
Murai, and Lee, 201847) – was markedly upregulated in both untreated and IR-treated AEG-1 
WT cells at all time-points, with the exception of 8 and 12 hours post-IR at 10 Gy (Fig. 8A, C). 
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p-ATR expression peaks in both WT and KO cells 4 hours post-IR at 2.5Gy; 8 hours following 
IR at 2.5Gy, WT cells are accumulated majority in G2/M (37.2%), while KO cells are 
accumulated in S-phase (59.1%). Prior to this time-point KO and WT cells show similar cell 
cycle profiles, indicating KO cells are arrested in S-phase at 8 hours while WT cells have 
continued progressing into G2/M (Fig. 5B). 
When probing for the downstream checkpoint proteins, p-Chk1 and p-Chk2, in the QGY-7703 
cells (Fig. 9) there appeared to be an upregulation of p-Chk2 in both IR-treated cell lines at all 
time-points, compared to the untreated cell lines. In the WT cells, p-Chk2 expression had more 
prominent upregulation from 30 minutes to 8 hours post-IR, while expression was increased in 
KO cells at 12 hours post-IR (Fig. 9A, right, and Fig. 9B, right). There did not appear to be a 
significant difference in p-Chk1 expression between the two IR-treated cell lines at 30 minutes 
and 4 hours, however, at 8 and 12 hours post-IR, there was increased signaling in KO cells 
compared to WT cells (Fig. 9A, left, and Fig. 9B, left). 
As for HuH7 cells, p-ATM signaling was initially increased in WT AEG-1 cells following IR at 
2.5Gy, but at 12 and 24 hours, KO cells demonstrated increased expression compared to WT 
cells (Fig. 10A), which is similar to what was observed in QGY-7703 AEG-1 KO cells at 8 and 
12 hours post-IR. Although p-BRCA1 expression was greater in irradiated WT cells compared to 
KO cells at 24 hours post-IR, at 36 hours irradiated KO cells had markedly increased signaling 
compared to WT (Fig. 10C). In fact, p-BRCA1 expression in KO and WT cells appeared to be 
downregulated at 30 minutes, 12 and 24 hours post-IR when compared to untreated cells, and 
this downregulation persisted in KO cells until 36 hours, at which point its expression was 
upregulated compared to untreated cells. Interestingly, p-BRCA1 expression in WT cells never 
increased in the irradiated cells when compared against untreated cells at all time-points. 
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Analysis of p-ATR did not show a remarkable difference between the IR-treated WT and KO 
clones (Fig. 10B) at 30 minutes and 12 hour post-treatment. However, at 24 hours, the WT cells 
had increased expression in both untreated and irradiated circumstances. At 36 hours, p-ATR 
was upregulated in KO irradiated cells compared to untreated cells, while it was downregulated 
in irradiated WT cells at this time-point.  
The downstream signaling kinases p-Chk1 and p-Chk2 in HuH7 cells did not show a similar 
pattern of expression as in the QGY-7703 cells. p-Chk1 expression (Fig. 10E) was increased in 
irradiated WT cells compared to KO cells at all time-points, although p-Chk1 in the untreated 
WT cells was also higher than untreated KO cells at 12, 24, and 36 hours post-thymidine release. 
p-Chk2 expression (Fig. 10D) on the other hand was greater in irradiated KO cells than WT cells 
at 30 minutes, 12 hours, and 36 hours. However, compared to untreated cells, p-Chk2 expression 
was upregulated at 30 minutes and 24 hours in irradiated WT and KO clones, which we did not 
observe in p-Chk1 expression. 
BCCIP is upregulated in AEG-1 KO mice liver tissue, but not in an in vitro system 
Due to evidence indicating BCCIP downregulation induced by AEG-1 overexpression in prostate 
tumor cells (Ash et al. 2008), we sought to replicate this observation in HCC cells. Although 
immunohistochemistry staining of BCCIP in mouse hepatic tissues showed upregulation of 
BCCIP in the AEG-1 KO samples (Fig. 12A), we were unable to replicate similar results in 
immunofluorescence staining of DihXY or QGY-7703 AEG-1 KO cells (Fig. 12C). Western blot 
analysis for BCCIP showed a band approximately 45 kDa that appeared to be downregulated in 
the DihXY AEG-1 WT clone; however, this band was not observed in the mouse hepatic 
samples (Fig. 12B). Bands closer to the theoretical size of BCCIP, approximately 36 kDa, were 
downregulated in two of the mouse hepatic samples, but were unchanged in the DihXY samples. 
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In HuH7 cells released from a double thymidine block, there did not appear to be a marked 
difference in BCCIP expression between the untreated cell lines, although expression was 
increased in KO cells compared to WT cells to some extent at 30 minutes, 12 hours, and 36 
hours following release (Fig. 13B). 
BCCIP is upregulated in HCC cells following low-dose IR 
Because BCCIP is involved in the HRR pathway, we reasoned that inducing DSB’s via IR could 
clue us in to why we were not observing an upregulation of BCCIP in the AEG-1 KO cells. We 
hypothesized that BCCIP upregulation in AEG-1 WT cells could be an underlying factor in their 
resistance to radiation treatment. Protein expression of BCCIP in QGY-7703 cells (Fig. 13A) 
corroborated our hypothesis that AEG-1 WT HCC cells upregulate BCCIP and are resistant to 
IR. Untreated WT cells and cells treated with 2.5 Gy demonstrated higher expression of BCCIP 
than KO cells at 0, 4, and 8 hours post-thymidine-release or post-IR; furthermore, BCCIP was 
not upregulated in KO cells at 8 hours post-IR. However, in UT KO cells was BCCIP expression 
was higher than that of WT cells. Interestingly, immunofluorescence of BCCIP (Fig. 13C) was 
steadily increased in AEG-1 KO cells at all time-points following IR at 2.5 Gy. The expression 
profile of BCCIP in QGY-7703 WT and KO cells is therefore parallel to p-p53 and p21 
expression in response to low-dose IR. 
Although BCCIP upregulation in response to IR was confirmed through both IF and western blot 
analysis in the QGY-7703 cell lines, this was not observed in the HuH7 cell lines. Protein 
expression of BCCIP in HuH7 AEG-1 KO cells was downregulated to a greater extent than WT 
cells at 30 minutes and 24 hours post-treatment with 2.5Gy IR (Fig. 13B). Interestingly, BCCIP 
expression was increased in AEG-1 KO cells at 12 and 36 hours post-IR when compared against 
IR-treated WT cells. These results conflict with both the observation of BCCIP upregulation in 
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IR-treated compared to untreated cells,, and BCCIP upregulation in WT compared to KO cells, 
in the QGY-7703 cell lines. 
AEG-1 expression in HCC cells is upregulated following ionizing radiation 
An unexpected result we observed in the radiation studies was increased AEG-1 signaling in 
QGY-7703 cells treated at 2.5Gy, as indicated by both western blotting (Fig. 8D, Fig. 13A) and 
immunofluorescence (Fig. 13C). This increase in signaling was observed by western blotting at 
30 minutes until 8 hours post-treatment, but not at 12 hours (data not shown). Meanwhile, AEG-
1 signaling was markedly increased in the IF images at 30 minutes post-treatment. However, this 
increase in AEG-1 signaling was not observed in the HuH7 AEG-1 WT cells (Fig. 10F). 
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Figure 1 Knockout of AEG-1 reduces cell survival and viability in control, untreated 
QGY-7703 cells, but not HuH7 cells. (A) Western blot images demonstrate expression 
status of AEG-1 in the QGY-7703 clones and HuH7 clones. GAPDH was used as an internal 
control. QGY-7703 cells were assessed for cell survival in (B) colony formation assay and 
cell viability in (C) MTT assay. Cell viability – measured by the average absorbance at 
600nm – of QGY-7703 AEG-1 KO and partial KO cells were normalized against AEG-1 
WT cells. (D) Cell viability of HuH7 cells using the MTT assay, shown by the average 
absorbance of AEG-1 WT cells normalized against AEG-1 KO cells. Although KO cells had 
increased proliferation at all time-points, WT cells showed a sharp increase in cell 
proliferation after two days of incubation. (E) Colony formation of HuH7 cells showed there 
was no significant difference in cell survival between the AEG-1 WT and KO cell lines.  
* P<0.05. 
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Figure 2 AEG-1 knockout slows cell cycle progression in HCC cells. Cells were treated with a 
double thymidine block, released into S-phase, and then collected for FACS cell cycle analysis at 
various time-points. Graphs display the percentage of cells in the total population (>10,000 
events per sample) that were in G1/G0, S, or G2/M based on nuclear staining profile. (A) 
Averaged cell cycle data of three independent experiments using QGY-7703 cells stained with 
either PI or 7-AAD. (B) DihXY cells stained with PI. After 24 hours, KO cells are maximally in 
G1/G0 while WT cells are continuing progression into S and G2/M. (C) QGY-7703 cells stained 
with 7-AAD. 4 hours after release, AEG-1 WT cells have returned to G1, while AEG-1 KO cells 
are still cycling through G2/M. AEG-1 WT cells completes two cycles after 12 hours, while 
AEG-1 KO completes 1 cycle. (D) HuH7 cells stained with PI. At all time-points, there are 
increased AEG-1 WT cells accumulated in G1/G0 compared to AEG-1 KO cells. 
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Figure 3 Knockout of AEG-1 reduces in vitro wound healing and invasion in QGY-7703 
and HuH7 cells. Matrigel invasion assay and wound healing assays were used to assess 
invasive and migratory capacities, respectively, of QGY-7703 and HuH7 cell lines. (A) AEG-
1 WT and partial KO cells showed significantly increased invading cells per field compared to 
AEG-1 KO cells in the QGY-7703 cell line (top). Similarly, AEG-1 KO in HuH7 cells 
significantly reduced the average number of invading cells (bottom). (B) AEG-1 KO cells had 
significantly reduced migration in the first 24 hours compared to AEG-1 WT cells in the 
QGY-7703 cell line (top). In the HuH7 cell line, the A6 AEG-1 KO cell line had significantly 
reduced total migration compared to both A5 and A12 AEG-1 WT cell lines (bottom). (C) 
Representative images of invading cells per field from the QGY-7703 cell line. (D) 
Representative images of QGY-7703 cell lines in the matrigel invasion assay at 0, 24, and 48 
hours following generation of the wound. (E) Representative images of invading cells per 
field from the HuH7 cell line. (F) Representative images of HuH7 A6 and A12 cell lines in the 
matrigel invasion assay at 0, 24, and 48 hours following generation of the wound. 
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Figure 4 Knockout of AEG-1 sensitizes HCC cells to low-dose radiation treatment. 
Colony formation assay was used to assess cell survival following ionizing radiation at 
various doses. QGY-7703 cells (A) and DihXY cells (B) showed significantly reduced 
survival in the KO cell line at 2.5 Gy. DihXY colony formation is shown as percent colony 
formation against control. (C) HuH7 cell survival was significantly reduced in the KO cell 
line following treatment at 2.5 Gy (left). Representative images of colonies in the WT and KO 
cell lines (right).  *P<0.05 
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Figure 5 In HCC cells, low-dose ionizing radiation induces greater G2/M accumulation 
in AEG-1 WT cells, while AEG-1 KO cells at later time-points. Cells were treated with 
2.5 Gy [(A) and (B)], or 10 Gy [(C) and (D)] and collected at various time-points. QGY-
7703 and HuH7 cells were double-stained with anti-BrdU and 7-AAD. DihXY cells were 
stained with PI. Graphs display the percentage of cells in the total population (>10,000 
events per sample) that were in G1/G0, S, or G2/M based on nuclear staining profile. (A) 
HuH7 cells treated at 2.5 Gy show increased G2/M accumulation at 12- and 24-hour time-
points in the AEG-1 WT cell line, while AEG-1 KO cells accumulate in G1/G0. (B) QGY-
7703 cells treated at 2.5 Gy show AEG-1 WT cells are maximally in G2/M at 8 hours, while 
AEG-1 KO cells accumulate in S-phase at 8- and 12-hour time-points. 
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Figure 6 Following low-dose IR of QGY-7703 AEG-1 WT cells, p-p53 and cyclin E protein 
expression are upregulated, while p21 and cyclin D1 protein expression are downregulated. 
QGY-7703 cells were collected for whole protein lysate following IR (2.5 and 10Gy) or release 
from double thymidine block (UT) at 30 minutes, 4 hours, 8 hours, and 12 hours. Lysates were 
then subjected to SDS-PAGE and probed for negative (A) and positive (C) regulators of the G1/S 
transition. (A) Western blot images showing expression of p-p53 and p21 in QGY-7703 cells 
(left) and quantification of expression relative to GAPDH (right). For p-p53, the lower band was 
used for quantification due to its proximity to the theoretical size of p-p53. P-p53 expression was 
increased in AEG-1 WT cells following IR at all time-points, while it was downregulated in 
AEG-1 KO cells at 30 minutes and 4 hours after IR. Meanwhile, p21 expression was 
downregulated in AEG-1 WT cells at all time-points following IR. In AEG-1 KO cells, p21 
expression was initially upregulated following IR, but after 8 hours its expression was 
downregulated. (B) Western blot images showing total p53 expression in QGY-7703 cell lines. 
GAPDH was used as an internal control. (C) Western blot images showing expression of Cyclins 
E and D1 (left) and quantification of expression of cyclin E relative to GAPDH (right). Cyclin E 
expression was upregulated in both KO and WT AEG-1 cells following both doses of IR. 
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Figure 7 After low-dose irradiation of HuH7 cells, cyclin E protein expression oscillates in 
both AEG-1 WT and KO cells, while p21 and cyclin D1 expression is consistently 
downregulated in both WT and KO cells. HuH7 cells were collected for whole protein lysate 
following IR (2.5Gy) or release from double thymidine block (UT) at 30 minutes, 12 hours, 24 
hours, and 36 hours. Lysates were then subjected to SDS-PAGE and probed for negative (A) 
and positive (B-C) regulators of the G1/S transition. (A) Western blot images showing 
expression of p21 (right) and quantification relative to EF1a. (B) Western blot images showing 
expression of cyclin E (right) and quantification relative to GAPDH (left). (C) Western blot 
images showing expression of cyclin D (right) and quantification relative to EF1a (left). 
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Figure 8 Low-dose ionizing radiation induces strong, rapid DSB signaling in AEG-1 
WT cells, while DSB signaling in AEG-1 KO cells begins at later time-points, in the 
QGY-7703 cell line. QGY-7703 cells were collected for whole protein lysate following 
ionizing radiation or release from double thymidine block at 30 minutes, 4 hours, 8 hours, 
and 12 hours. Lysates were then subjected to SDS-PAGE and probed for various DNA 
damage response markers. (A) Western blots showing total ATR and ATM (top) and p-
ATM, p-ATR, and gH2AX expression (bottom). p-ATR and p-ATM signaling were initially 
greater in AEG-1 WT cells at 30 minutes post-IR at 2.5Gy, while gH2AX signaling was 
greater in irradiated AEG-1 KO cells at 30 minutes. (B) Western blot showing p-BRCA1 
signaling was increased in AEG-1 KO cells following IR at 2.5 and 10 Gy compared to 
AEG-1 WT cells. (C) Protein expression for p-ATR, p-ATM, p-BRCA1, and gH2AX were 
quantified using ImageJ against their respective internal controls. (D) Representative blots 
of internal controls. AEG-1 expression was consistent with KO and WT cell lines. 
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  Figure 9 p-Chk2, but not p-Chk1, is upregulated in QGY-7703 AEG-1 WT and KO cells 
following low-dose IR. QGY-7703 cells were collected for whole protein lysate following 
2.5Gy IR or release from double thymidine block (UT) at 30 minutes, 4 hours, 8 hours, and 12 
hours. Lysates were then subjected to SDS-PAGE and probed for p-Chk1 and p-Chk2 
expression. (A) Western blot images of p-Chk1 and p-Chk2, and loading controls (far right). 
(B) Quantification of p-Chk1 (left) and p-Chk2 (right) expression relative to loading controls. 
p-Chk2 expression was immediately and persistently upregulated in both AEG-1 WT and KO 
cells after IR at 2.5Gy, while p-Chk1 was upregulated after 8 hours. Both proteins were 
strongly upregulated after IR at 10Gy. 
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Figure 10 HuH7 cells treated with low-dose IR do not show upregulated p-ATM, p-
ATR, or p-BRCA1 signaling, but show upregulation of p-Chk2 and p-Chk1 expression 
at later time-points. HuH7 cells were collected for whole protein lysate following IR 
(2.5Gy) or release from double thymidine block (UT) at 30 minutes, 12 hours, 24 hours, and 
36 hours. Lysates were then subjected to SDS-PAGE and probed for DDR signaling proteins. 
(A-C) Western blot images (top) showing expression of total ATM and p-ATM (A), total 
ATR and p-ATR (B), and p-BRCA1 (C), with quantification of the phosphorylated proteins 
relative to internal loading controls (bottom). (D-E) Western blot images of p-Chk2 (D), and 
p-Chk1 (E). (F) Representative western blot images of internal loading controls used for 
quantification of expression. (G) Quantification of p-Chk2 (left) and p-Chk1 (right) relative to 
GAPDH. 
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Figure 11 Knockout of AEG-1 induces increased histone H2AX phosphorylation 
following ionizing radiation. Representative confocal images of QGY-7703 cells stained 
for gH2AX fluorescence, with either no treatment (A) or ionizing radiation at 2.5 Gy (B). 
(C) gH2AX foci were quantified using ImageJ by finding maxima in each image. While 
both AEG-1 KO and WT untreated cells showed a similar number of gH2AX foci, the 
number of gH2AX foci was persistently and significantly increased in KO cells at all time-
points following IR. 
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(A) (B) 
* 
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Figure 12 BCCIP expression is upregulated in AEG-1 KO mouse hepatic liver cells, but 
not in DihXY or QGY-7703 AEG-1 KO cells. (A) Immunohistochemistry staining of mouse 
hepatic liver cells, stained with anti-BCCIP antibody. (B) Western blot probed for BCCIP in 
mouse hepatic whole protein lysates. Lanes 1-3 are wildtype for AEG-1; lanes 4-6 are AEG-1 
KO; lane 7 is DihXY wildtype for AEG-1; lane 8 is DihXYA8 knockout of AEG-1. (C) 
Representative immunofluorescence confocal images of DihXY cells (left) and QGY-7703 
cells (right) stained with anti-AEG-1 (red), anti-BCCIP (green), and DAPI (blue). 
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Figure 13 BCCIP expression is upregulated following ionizing radiation at 2.5 Gy in 
QGY-7703, but not HuH7, cells. (A) QGY-7703 AEG-1 KO and WT cells were collected 
at 30 mins, 4 hours, 8 hours, and 12 hours following either release from a double thymidine 
block (UT), or treated with 2.5 Gy and then assessed for BCCIP expression via western 
blotting. Protein expression was then quantified (right) relative to EF1a expression. (C) 
Representative confocal images of cells to detect BCCIP immunofluorescence in QGY-
7703 UT and irradiated cells. UT cells were not synchronized for IF imaging. Cells were 
stained with AEG-1 (red), BCCIP (green), and DAPI (blue). 
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CHAPTER 5 
DISCUSSION 
HCC is a highly lethal disease and its limited treatment options are discouraging for advanced-
stage patients with non-resectable tumors. Resistance to the targeted kinase inhibitor, Sorafenib, 
and to radiation therapy makes the situation even more grim. Regorafenib (StivargaÒ) has been 
the only targeted therapy to be approved for treatment of HCC patients in recent years, and is 
used in the context of patients whose tumors worsen during or after sorafenib treatment. 
In recent years, targeted gene therapy is becoming increasingly focused on as a method of 
overcoming issues with chemoresistance and radioresistance in multiple cancer types. However, 
phase III clinical trials using various targeted therapies in HCC patients have failed due to 
induced liver toxicity, low efficacy, or heterogeneity in the molecular background of HCC 
tumors. Targeting AEG-1 mRNA expression with a nanoparticle-delivery system has shown 
significant growth inhibition of orthotopic human xenografts in mice, indicating the protein 
could be a promising molecular target for treating HCC patients48.  
AEG-1 has been shown to be involved in the activation of numerous growth-promoting 
pathways, is potently upregulated in HCC, and promotes hepatocarcinogenesis in both in vitro 
and in vivo models10,14,16. The results from cell proliferation, invasion, and migration studies in 
the present study confirm the already well-characterized phenotypic effects of AEG-1 
upregulation. In HuH7 and QGY-7703 cells with deficient AEG-1 expression, there was a 
significant decrease in in vitro matrigel invasion and wound closure. These assays are well-
established methods to replicate the epithelial mesenchymal transition of carcinogenesis, which 
is the process by which tumor cells metastasize outside of the primary tumor site49. In the QGY-
7703 cell line, there was also a significant reduction of AEG-1 KO cell survival in the colony 
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formation assay, and a significant reduction in cell viability of AEG-1 KO cells in the MTT 
assay. Although we did not observe reduced cell viability and cell survival in the HuH7 AEG-1 
KO cell line, the KO cells showed significantly lower migration and invasion, which eliminates 
cell proliferation as a confounding variable in the wound closure and matrigel invasion assays. 
Furthermore, in the growth curve of the HuH7 cells, AEG-1 WT cells exhibit a sharp increase in 
cell proliferation after 2 days of incubation. An explanation for these conflicting results is that 
the HuH7 and QGY-7703 KO cell lines are phenotypically different from each other in their 
capacity to proliferate due to the variability inherent in picking random clones produced from 
CRISPR/Cas9. Regardless, from these results, and from western blot imaging of AEG-1 
expression, we were confident that AEG-1 knockout was established in the cell line and was 
producing the expected phenotypic effects. 
Because cell proliferation was significantly reduced in the QGY-7703 AEG-1 KO cells, we 
reasoned that cell cycle progression must also be delayed in the KO cell line. In maintenance of 
the cell lines, QGY-7703 cells become confluent at least 1-2 days sooner than HuH7 or DihXY 
cells. Double-thymidine block and cell cycle characterization have also previously been 
established in the QGY-7703 cell line50. We therefore chose to use 0, 4, 8, and 12 hours as time-
points for cell cycle analysis in the QGY-7703 cell line. DihXY cells become confluent 
approximately one day slower than QGY-7703 cells, and so 0, 4, 8, 12, 16, and 24 hours cell 
cycle time-points were chosen for the this study. Finally, HuH7 cells reach confluency slowest 
among the cell lines. We initially collected HuH7 cells every 6 hours for 48 hours for cell cycle 
analysis (data not shown). Upon analysis, we identified that HuH7 cells complete a full cell cycle 
at 36 hours. Subsequently, 0, 12, 24, and 36 hours were chosen for cell cycle analysis. Across the 
DihXY, HuH7, and QGY-7703 cell lines, cell cycle progression was consistently reduced at all 
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chosen time-points in the AEG-1 knockout clones. This deceleration in cell cycle progression 
was more readily apparent in the QGY-7703 AEG-1 KO cells than in the other cell lines. One 
explanation for this observation is that AEG-1 is expressed to a much higher degree in the QGY-
7703 AEG-1 WT cells compared to the HuH7 AEG-1 WT cells (see Yoo et al. 2009, Fig. 1A11), 
indicating QGY-7703 cells may be more addicted to AEG-1 expression and therefore proliferate 
faster. 
The present study identifies AEG-1 as a potential target in sensitizing radioresistant HCC tumors 
to radiation treatment. By using three different cell lines modeling HCC, we have shown that 
knockout of AEG-1 promotes sensitization to radiation at a clinically relevant dosage of 2.5Gy. 
While ionizing radiation at 10Gy proved completely cytotoxic to both AEG-1 WT and KO cells 
across all cell lines, there was a significant reduction in cell viability in AEG-1 KO cells treated 
with 2.5Gy. These results prompted us to assess protein expression of cell cycle regulatory 
molecules and of signaling and effector molecules involved in the DNA damage response 
pathway. 
Appropriate DNA replication, cell cycle progression, and mitosis are all required for accurate 
chromosome segregation and maintenance of genomic stability. Normally, cells that fail to abide 
by these tightly regulated pathways are directed to apoptosis; however, cancer cells can finetune 
expression of oncogenes or tumor suppressor genes to persist despite errors in mitosis or cell 
cycle checkpoints. BCCIP is one of many proteins involved in the G1/G0 transition in the cell 
cycle, along with spindle pole stabilization during mitosis. We were initially interested in 
studying BCCIP expression in the context of AEG-1 knockout due to evidence that BCCIPa 
directly interacts with AEG-1 in prostate tumor cells. Furthermore, Ash et al. provided evidence 
that AEG-1 overexpression leads to proteasomal degradation of BCCIP, suggesting a potential 
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role of AEG-1 expression in abrogating the G1/S checkpoint44. Although we observed increased 
anti-BCCIP staining in IHC of AEG-1 KO mouse hepatic tissue samples compared to AEG-1 
WT samples, we did not observe this difference in IF staining of DihXY or QGY-7703 cells. 
BCCIP appeared to be primarily localized to the nucleus with faint signaling in the cytoplasm, as 
seen in the DAPI-merged IF images. This localization is consistent with prior evidence that both 
BCCIPa and BCCIPb are localized to the nucleus under confocal microscopy37. Furthermore, 
we did not observe a noticeable change in BCCIP localization in either the untreated or irradiated 
AEG-1 WT QGY-7703 cells. The present study therefore provides new evidence that BCCIP 
localization is not affected by ionizing radiation in HCC cells. 
After observing conflicting evidence of BCCIP signaling in IHC and IF assays, we sought to 
analyze BCCIP protein expression in untreated and irradiated HCC cells. Unexpectedly, BCCIP 
expression was increased in QGY-7703 AEG-1 WT cells at all time-points except for 12 hours 
post-thymidine release, when compared to AEG-1 KO cells. Although FACS analysis of both 
WT and KO cells at 12 hours show accumulation in G1/G0 phase, this decrease in BCCIP 
expression in AEG-1 WT cells indicates a lack of G1/S checkpoint in the WT cells as they 
continue unrestricted proliferation, which corroborates prior evidence that downregulation of 
BCCIP in hepatocytes promotes G1/S transition and increases cell proliferation39. On the other 
hand, BCCIP expression in the untreated HuH7 cell line was minimally upregulated in AEG-1 
KO cells compared to WT cells at all time-points, except 24 hours, actually confirming the 
findings of Ash et al44. Furthermore, BCCIP expression was markedly increased in the AEG-1 
WT cells of both QGY-7703 and HuH7 cell lines at 30 minutes post-IR, but its expression was in 
fact downregulated in the HuH7 cells, while upregulated in the QGY-7703 cells, compared to 
their untreated counterparts, at this initial time-point. This conflicting pattern of BCCIP 
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expression in the QGY-7703 and HuH7 AEG-1 WT cell lines may be attributed to the TP53 
mutational status of the HuH7 cell line. While QGY-7703 cells contain wildtype TP53, HuH7 
cells overexpress a mutant p53 that exhibits a longer half-life – when compared to p53 of other 
HCC cell lines and to normal liver cells – due to a point mutation in the coding region of 
TP5351,52. 
Because BCCIP has roles in both cell cycle regulation and homologous recombination repair, it 
is difficult to attribute the upregulation of BCCIP in the irradiated QGY-7703 AEG-1 WT cells 
to a specific pathway. Hence, the expression of BCCIP cannot be examined in a 
compartmentalized manner. In a more comprehensive view of proteins involved in the DNA 
damage response, we observed stronger, more rapid expression of p-ATM, p-ATR, and gH2AX 
– all involved in signaling for initiation of homologous recombination repair – in the irradiated 
AEG-1 WT cells than in the AEG-1 KO cells. Although p-ATM, gH2AX, and p-ATR in QGY-
7703 signaling in AEG-1 WT cells was initially stronger (30 minutes post-IR) compared to 
AEG-1 KO cells, the expression pattern switched at subsequent time-points to be increased in 
AEG-1 KO cells compared to WT cells. Similarly, p-BRCA1 and p-Chk1 expression showed a 
sharp increase in HuH7 irradiated AEG-1 WT cells at 24 hours post-IR, and their expression was 
higher in HuH7 irradiated AEG-1 KO cells at 36 hours. Analysis of the downstream checkpoint 
kinase p-Chk2 showed that its expression was increased in the QGY-7703 AEG-1 WT cells at 30 
minutes until 8 hours post-IR at 2.5Gy, after which the irradiated AEG-1 KO cells showed 
increased expression. This can be explained by an initial, rapid activation of ATM, ATR, 
BRCA1, and gH2AX signaling, as observed in the AEG-1 WT cells at 30 minutes post-IR, which 
is subsequently followed by more rapid activation of p-Chk2 and p-Chk1 in the AEG-1 WT 
cells. Therefore, there is reliable evidence that AEG-1 WT cells induce the DDR more rapidly, 
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and is a possible mechanism by which DSB’s are repaired more efficiently by AEG-1 
overexpressing cells to protect HCC from low-dose ionizing radiation. 
A potential limitation of our findings is that p-Chk1 and gH2AX signaling can be indicators of 
the DNA damage response, but are not specific to this process51. Immunofluorescence staining of 
gH2AX is used to demonstrate DDR foci in cells treated with IR. In response to DNA damage, 
gH2AX is phosphorylated on its Ser139 residue and signals for mediator of DNA damage 
checkpoint 1 (MDC1) to directly bind gH2AX at its BRCT domain. This is required for 
recruitment of DDR complexes such as 53BP1 to repair damaged DNA53,54. However, H2AX 
phosphorylation is also implicated in replication stress and checkpoint abrogation55,56. 
Nevertheless, because we also observed an upregulation of p-ATM and p-chk2 expression in 
conjunction with gH2AX signaling, we provide convincing data that DSB-induced signaling is 
initiated in QGY-7703 AEG-1 WT cells more rapidly than in KO cells. 
In the present study we observed p-ATR expression was upregulated in AEG-1 WT cells after IR 
at 2.5Gy. In fact, p-ATR expression was consistently upregulated in QGY-7703 AEG-1 WT cells 
at all time-points following IR at 2.5Gy. The results were not as remarkable in HuH7 AEG-1 WT 
cells, but we did observe marked, increased upregulation of p-ATR expression at 24 hours post-
IR when compared to AEG-1 KO cells. We therefore became interested in the possibility of WT 
AEG-1 cells protecting cells from low-dose ionizing radiation through increased replication fork 
stabilization. Cancer cells have higher baseline rates of replication due to oncogenic drivers and 
therefore may have increased incidence of replicative stress in the absence of genotoxic 
stressors52. In the context of HCC, non-transformed hepatocytes are quiescent and normally 
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divide only rarely, making them susceptible to replicative stress57. Hepatic cells may therefore 
have increased replication fork protection at a basal level, even prior to carcinogenesis. 
DNA replication stress encompasses any endogenous or exogenous stressor that can induce 
replication fork stalling or damage, generating exposed single-stranded DNA and inducing the 
intra-S-phase checkpoint. Replication stress is sensed by ATR, which autophosphorylates and 
relays the signal to the Chk1 effector kinase. BRCA1, BRCA2, and the Fanconi anemia family of 
proteins are required for MRE11 nuclease to protect nascent DNA strands at stalled replication 
forks. While they use very similar proteins in their processes, HRR and replication fork 
protection are functionally separate58,59. Topoisomerase IIβ-binding protein 1 (TopBP1) activates 
ATR and is required for resolving replication stress to prevent formation of 53BP1 nuclear 
bodies. Ultimately, ATR activation in response to replication stress is fundamental to protect 
genomic integrity and repair stalled replication forks prior to mitotic entry. Therefore, an intra-S-
phase checkpoint is induced while replication forks are repaired in the presence of stress. 
Replication stress can be a result of too few origins of replication or insufficient activation of 
these origins; activation of too many origins of replication, which can lead to depletion of 
histones or DNA binding protein RPA and subsequently the collapse of replication forks. 
Replication stress can also be induced by exogenous stressors, including UV-light or genotoxic 
agents - such as hydroxyurea, cisplatin, mitomycin C, and camptothecin. There is also mounting 
evidence that activation of oncogenes results in replication stress by affecting origin firing, 
nucleotide depletion, or changing temporal stability of the cell cycle 61,62. The present findings 
identify a previously unexplored role of AEG-1 expression in protecting HCC cells from 
radiation therapy through upregulation of p-ATR. Further investigation needs to be conducted on 
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AEG-1 in protecting replication forks before we can positively conclude that this is another 
pathway through which AEG-1 induces radioresistance. 
Recently, whole genome sequencing, whole exome sequencing, and RNA-sequencing of 751 
distinct HCC tissues identified a subgroup of HCC tumors that contain mutated CCNE1 
(encoding cyclin E) or CCNA2 (encoding cyclin A2) from patients who developed HCC in a 
non-cirrhotic background. The lab identified recurrent CCNA2 fusions and CCNE1 promoter 
region rearrangements60. Cancers with such mutational backgrounds are characterized by high 
amounts of replication stress due to increased proliferation rates62. The present study showed 
cyclin E upregulation in untreated HuH7 AEG-1 KO cells at 12, 24, and 36 hours post-thymidine 
release, and in irradiated AEG-1 KO cells at 30 minutes, 12, and 36 hours post-IR at 2.5Gy. On 
the other hand, cyclin E protein expression was upregulated in untreated QGY-7703 AEG-1 WT 
cells at 30 minutes and 4 hours post-thymidine release, while AEG-1 KO cells had increased 
expression at 8 and 12 hours. In both AEG-1 WT and KO QGY-7703 cells, cyclin E was 
consistently upregulated at all time-points at both 2.5 and 10Gy dosages. Cyclin E expression 
patterns in QGY-7703 cells, along with our observations of upregulated p-ATR signaling in 
QGY-7703 cells across all time-points, is consistent with prior reports that cyclin E upregulation 
is associated with ATR upregulation in HCC64. Furthermore, evidence in our study of both cyclin 
E and p-ATR overexpression in irradiated QGY-7703 cells point to induction of replication 
stress in these cells in response to IR, as cyclin E regulation is implicated in appropriate origin of 
replication firing55. 
Along the same line of reasoning, our observations of cyclin E upregulation, yet slowed cell 
cycle progression, in the irradiated QGY-7703 cells can be attributed to p-Chk2 upregulation. P-
Chk2 has been shown to inhibit enzymatic activity of the cyclin E/Cdk2 complex21. As we 
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observed a strong increase in p-Chk2 expression in the irradiated QGY-7703 cells, there is a 
possibility that p-Chk2 is interacting with the cyclin E/Cdk2 complex to delay cell cycle 
progression, while transcription of CC2NE1 is upregulated. 
An unexpected finding of this study was upregulation of AEG-1 expression in QGY-7703 cells 
in response to ionizing radiation, as was evidenced by both western blot analysis and confocal 
microscopy. A current literature search only shows one prior study of AEG-1 expression in the 
context of ionizing radiation. However, this study focused on preventing recurrence of distant 
metastatic tumors in rectal cancer patients through AEG-1 knockdown66. The present study 
therefore provides evidence that AEG-1 itself is upregulated in response to ionizing radiation in 
HCC cells, along with affecting protein expression of DDR kinases. There are multiple ways 
through which protein expression of AEG-1 is upregulated in HCC: genomic amplification, post-
translational monoubiquitination, transcriptional activation by c-myc, downregulation of miR-
375, and/or binding of cytoplasmic polyadenylation element-binding protein 1 (CPEB1) to AEG-
1 mRNA to activate its translation67,68. The mechanism by which AEG-1 is upregulated 
following IR treatment can be the focus of a future project. 
A limitation of the present study is that use of the CRISPR/Cas9 system to knockout a gene 
comes with several drawbacks. One of these drawbacks is potential off-target effects that the 
vector may induce in the selected clones. Until full genomic profiling is conducted on the cell 
lines, the possibility of insertional or deletion mutations in genes other than the intended target, 
AEG-1, must be considered. Furthermore, the clones selected for these studies are randomly 
generated and selected, and each clone may be slightly phenotypically or genetically different 
from another. However, as previously described, AEG-1 expression can be upregulated in a 
number of ways, including through genomic amplification. Complete deletion of the gene in 
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three diverse HCC cell lines was a feat in and of itself, and has provided considerable critical 
insight needed to address the aims established for this project. These concerns can be addressed, 
and the results of this study validated, by selecting multiple AEG-1 knockout clones from each 
cell line in future projects, or replicating the results in vivo using the Cre/lox conditional 
knockout system to abrogate AEG-1 expression. 
We conclude that AEG-1 expression protects HCC cells from low-dose ionizing radiation 
through two mechanisms: 1) initiating the DNA damage response rapidly and efficiently; and 2) 
increasing replication fork stabilization in the face of replication stress. The scope of this study 
did not fully address the mechanistic role of AEG-1 expression in resolving stalled replication 
forks or in promoting more rapid DSB repair, and therefore needs to be clarified in future 
studies. Regardless, the results described here do give us a promising method of sensitizing 
radioresistant HCC tumors through abrogation of AEG-1 expression.  
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CHAPTER 6 
FUTURE DIRECTIONS 
Although our results are exciting, they must be replicated in vivo to establish validity in their 
ability to be translated to the clinic. A Cre/lox model of liver-specific AEG-1 knockout in mice, 
with subsequent DEN-induced liver tumor formation, can be used to demonstrate replicability of 
sensitization to ionizing radiation in AEG-1 deficient HCC cells. Another viable method would 
be to use nanoparticle delivery of AEG-1 siRNA (as described by Rajasekaran et al. 201548) in 
combination with radiation therapy in mice containing xenografts of QGY-7703 or HuH7 
parental cell lines48. 
A major question we are left with after the results described here is whether p-ATR upregulation 
induced by AEG-1 expression in irradiated HCC cells is due to replication fork stabilization. 
Activated ATR has diverse functions in both DSB and SSB repair; therefore, it is crucial that we 
identify in which functional pathway p-ATR is being used to protect HCC cells from IR. There 
are several ways to identify activation of the replication stress response. Possibly the simplest 
method is the cell cycle restart assay, in which cells are treated with hydroxyurea to deplete 
dNTP’s. Other methods involve quantification of replication foci or origins. IF staining of IdU – 
a thymidine analog – can be used to quantify replication foci in early S-phase cells. Additionally, 
DNA fiber analysis quantifies firing of replication origins and distances between origins69. A 
more complex but comprehensive method would be to analyze the genetic expression patterns of 
replication-stress-associated genes in both untreated and irradiated AEG-1 KO and WT cells. A 
recent paper used a cell line with diminished ATR expression to generate a replication stress 
defect signature through microarray analysis. A similar model could be created by knockdown of 
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ATR, via short hairpin RNA, in HuH7 and QGY-7703 cell lines to compare against the 
replication stress gene signature of irradiated cells70. 
Several inhibitors that target proteins involved in the cell cycle have been previously studied in 
HCC models. The Wee1 kinase inhibitor AZD1775 has recently been shown to sensitize HCC 
cells to radiation treatment. Wee1 is a Ser/Thr kinase that was originally identified in the fission 
yeast S. pombe. The human homologues for Wee1 are Wee1A and Wee1B. Wee1 kinase is 
involved in G2 checkpoint regulation and replication initiation via inhibition of CDK1, and 
Wee1 kinase activity is implicated in preventing replication stress and inappropriate DNA 
replication. In Hep3B and HuH7 HCC cell lines, Cdk1 phosphorylation – which is an indicator 
of G2 arrest – was increased when treated with ionizing radiation, but this arrest was absent 
when radiation was combined with AZD1775 treatment44. Another recent paper has also 
reviewed evidence that a combination of ATR and Wee1 kinase inhibitors can target both 
replication fork stabilization and HRR in cancerous cells29. Although phase I and II clinical trials 
are currently underway to target ATR, CHK1, and WEE1, these are not being studied in the 
context of HCC62. Therefore, a study using a panel of ATR, Wee1, and Chk1 kinase inhibitors in 
our model can provide insight as to whether knockout of AEG-1 induces increased sensitivity of 
HCC cells to these inhibitors, as well as provide rationale for using such inhibitors in an in vivo 
model of HCC. The results could also clue us into how AEG-1 interacts with these diverse 
signaling proteins to induce radioresistance. 
Aurora kinases are serine/threonine kinases involved in maintaining appropriate cell cycle 
progression and genomic stability. Inhibiting aurora kinases induces a postmitotic checkpoint 
and accumulates cells in a pseudo-G1 state that requires p53. Prior studies have shown 
aggressive HCC with poor prognosis correlated with overexpression of aurora kinases A and 
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B71,72. The same lab that identified Aurora kinases A and B overexpression in HCC then showed 
that HCC can be sensitized to radiation when treated with the broad aurora kinase inhibitor VE-
46573. Although expression of aurora kinases were not analyzed in the present study, observing 
the effect of wide-spectrum aurora kinase inhibition in an AEG-1 KO model could be another 
avenue of investigating how AEG-1 interacts with cell cycle regulators. 
In addition, the exact mechanism through which AEG-1 interacts with the DNA damage 
response is still unclear. AEG-1 is a potent upregulator of the PI3K/Akt and RAF-1-MEK1/2-
ERK1/2 pathways. These signaling pathways are pro-survival and have been shown to be 
activated in response to ionizing radiation in various cancer cell types. Ionizing radiation at low, 
clinically-relevant doses (1-2 Gy) induces phosphorylating activation of epidermal growth factor 
receptors ERBB1 and HER1 due to generation of reactive oxygen species and reactive nitrogen 
species in the mitochondria, which reduce protein tyrosine phosphatase activity of ERBB1 and 
HER1. This reaction occurs during the initial response to ionizing radiation. Following several 
hours, it is hypothesized that ERK1/2 and Akt signaling can change cyclin expression profiles, 
along with affecting levels of pro-cell survival molecules Bcl-2, Bcl-XL, MCL-1, c-FLIP, XIAP, 
IAP1, and pro-apoptotic molecules BAD and BIM. This in turn allows for survival of a small 
subset of the cell population to continue actively proliferating despite radiation treatment74,75,76. 
There is also evidence that tumors containing H-RAS, K-RAS, or N-RAS mutations may also be 
protected from ionizing radiation because they too can activate the PI3K pathway 
inappropriately. Targeting PI3K signaling using small molecule inhibitors sensitizes these tumor 
cells to ionizing radiation77. In order to discern whether knockout of AEG-1 itself has a 
functional effect on reducing the DNA damage response, or if dampening of PI3K/Akt/ERK1/2 
signaling as a result of AEG knockout induces sensitization to radiation treatment, it would be 
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prudent to repeat the radiation studies in in vitro models with depletion of PI3K/Akt signaling in 
AEG-1 WT clones, or reconstitution of the pathway in AEG-1 KO clones. 
Finally, because our findings of BCCIP expression in the context of AEG-1 expression conflict 
with both the literature44 and within our study between the QGY-7703 and HuH7 cell lines, it is 
evident that replicating Ash et al.’s co-immunoprecipitation of AEG-1 with BCCIP must be 
conducted in multiple HCC cell lines. Further investigation of this interaction between AEG-1 
and BCCIP can clarify the role of BCCIP function in the context of AEG-1 overexpressing HCC 
cells, as well as identify possible heterogeneity in their interaction across various HCC cell lines.  
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